Status:
COMPLETED
Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This trial is conducted in the United States. The aim of this clinical trial is to investigate whether chronic liraglutide administration affects the mode of action (pharmacokinetics) of insulin detem...
Eligibility Criteria
Inclusion
- Diagnosed with type 2 diabetes
- BMI less than 45.0 kg/m2
- Insulin naive
- Currently treated with Oral Anti-Diabetic drugs (OADs) and metformin with a HbA1c between 7.0 and 9.5% or currently treated with metformin only with a HbA1c between 7.0 and 10.0%
Exclusion
- Any clinically significant disease other than type 2 diabetes
- Currently using daily insulin
- Thiazolidinione use or other injectable diabetes medications within the last 3 months
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00873223
Start Date
March 1 2009
End Date
September 1 2009
Last Update
January 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Chula Vista, California, United States, 91911